Pfizer presented new data on sigvotatug vedotin, its lung cancer drug, after a failed Phase 3 trial, highlighting a 2.5-month survival benefit in a ...

The INTerpath-001 trial randomized 1,137 patients with resected stage IIB to IV melanoma to Keytruda alone or Keytruda plus ...

Moderna's stock plunged on Thursday, startling investors. But the company remains one of this year’s hottest biotech ...

Moderna gave investors a scare as its stock plunged on Thursday. But it's still one of the hottest biotechs this year. And it's hardly alone – the sector is on a roll and looks poised for more gains.

Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...

The vaccine, called intismeran, is tailored to each patient’s tumour. The findings, which measured recurrence risk over two ...

Moderna and Merck stocks fell as new melanoma vaccine trial data showed a 42% recurrence reduction, missing investor ...

The companies had initially announced in August that the bespoke vaccine led to significant and clinically meaningful ...

A combination of the personalized cancer vaccine intismeran autogene and Merck's Keytruda just barely cleared analysts’ ...

The data were not bad — in fact, the outcome was better than many analysts had predicted. The problem was Cambridge-based ...

A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% ...

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before ...